Experimental cell therapy for children with relapsed or resistant leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an experimental treatment called BG1805 for children with acute myeloid leukemia (AML) that has returned or not responded to standard therapy. BG1805 is a type of cell therapy (like CAR-T) that targets the CLL-1 marker on leukemia cells, potentially helping the body fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- The child must be between 3 and 18 years old and weigh at least 10 kg (about 22 pounds).
- The leukemia must be acute myeloid leukemia (AML) that has come back after treatment or has not responded to standard treatments.
- A lab test must show that the leukemia cells have a certain marker called CLL-1 (at least 50% of cells).
- The child must have recovered from side effects of previous treatments and be well enough to participate (performance status 0-1).
- The child must not have had certain other cancer treatments like CAR-T therapy before.
- The child must not have uncontrolled infections or a history of severe allergic reactions to the study drug components.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment, BG1805, for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. It targets a specific marker on leukemia cells called CLL-1.
This trial tests a new treatment using the patient's own immune cells, modified to find and attack leukemia cells that remain after initial chemotherapy. It's for children with B-cell acute lymphoblastic leukemia who still have tiny amounts of cancer cells detectable after standard treatment.
This trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD22) found on leukemia cells. It is for children and young adults whose B-ALL has come back multiple times, or who have not responded to other treatments.
This trial tests an investigational therapy (CT1390B) for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. It aims to see if the therapy is safe and helps patients with a specific marker called CLL-1.
This trial tests a new type of immunotherapy called CAR-T cells, which are made from your own blood cells and trained to find and destroy leukemia cells. It is for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments.
This trial tests a new type of immune cell therapy (CAR-T) designed to find and kill leukemia cells that carry two specific markers (CLL-1 and CD33). It is for adults with acute myeloid leukemia that has come back or is not responding to standard treatments.
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.